decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
Appendix E - National Coverage Determinations Manual / 220.6.15
Subscribe or sign in to view the full article.
Article Overview
This page explains a Medicare National Coverage Determination covering FDG PET for cancer indications not previously specified, with emphasis on coverage with evidence development. It is relevant to coders, compliance teams, oncology providers, imaging facilities, and reimbursement staff who need to understand the general policy framework, the types of qualifying prospective clinical studies referenced, and where CMS says access information will be posted. The article is a policy update from CMS and includes effective and implementation dates.
Why This Topic Matters
It helps readers identify when this Medicare coverage policy applies and understand the broad evidence-development context surrounding FDG PET cancer services.
What You Will Learn
- How Medicare frames coverage for certain FDG PET cancer services under evidence development
- What general types of prospective clinical studies are referenced in the policy
- Where CMS indicates access and notice information will be published
- The effective, implementation, and review timing associated with the policy update
Who Should Read This
- Medical coders
- Coding auditors
- Compliance professionals
- Oncology providers
- Radiology and nuclear medicine staff
- Hospital billing staff
- Revenue cycle teams
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com